Takeshi Takagaki
Suita, 5640053, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Population pharmacokinetics of blonanserin in Japanese adolescent and adult patients with schizophrenia.
Journal: Drug metabolism and pharmacokinetics
Published: January 16, 2024
Prediction of Corresponding Dose of Transdermal Blonanserin to Oral Dose Based on Dopamine D2 Receptor Occupancy: Unique Characteristics of Blonanserin Transdermal Patch.
Journal: Journal of clinical psychopharmacology
Published: April 06, 2022
Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of EPI-589 in Healthy Participants.
Journal: Clinical pharmacology in drug development
Published: January 12, 2022
Effects of a reactive oxygen species generator, napabucasin (BBI608), on tolerability, safety, pharmacokinetics, and QT/QTc interval in healthy volunteers.
Journal: Pharmacology research & perspectives
Published: April 06, 2021
Pharmacokinetic Evaluation of Blonanserin Transdermal Patch: Population Analysis and Simulation of Plasma Concentration and Dopamine D2 Receptor Occupancy in Clinical Settings.
Journal: Journal of clinical pharmacology
Published: October 09, 2020
Pharmacokinetics, safety and metabolite profiling of minesapride, a novel 5-HT4 receptor partial agonist, in healthy elderly and young subjects.
Journal: Drug metabolism and pharmacokinetics
Published: March 24, 2020
Pharmacokinetics and Safety of Ranirestat in Patients With Hepatic Impairment.
Journal: Journal of clinical pharmacology
Published: January 29, 2020
Thorough QT/QTc Study Shows That a Novel 5-HT4 Receptor Partial Agonist Minesapride Has No Effect on QT Prolongation.
Journal: Clinical pharmacology in drug development
Published: November 17, 2019
Showing 1-8 of 8
Last Updated: 09/26/2026